Israel vs Tonga: Pneumococcal conjugate second or third-dose vaccines (PCVc) immunizati
Israel
94.0%
in 2025
Tonga
94.0%
in 2025
Israel rank
46th
Tonga rank
46th
Pneumococcal conjugate second or third-dose vaccines (PCVc) immunizati over time
- Israel
- Tonga
How they compare
Israel currently reports 94.0% against 94.0% in Tonga, a difference of 0.0%.
The two have swapped places 2 times across 18 shared years of data; in 2008 it was Tonga ahead.
Israel ranks 46th and Tonga ranks 46th of 194 countries.
Israel has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Israel | Tonga | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 84.4% | 0.0% | 84.4% | Israel |
| 2020s | 94.2% | 71.0% | 23.2% | Israel |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc) immunizati, Israel or Tonga?
- Israel, at 94.0% against 94.0% in Tonga as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) immunizati between Israel and Tonga?
- 0.0%, with Israel ahead.
- How many years of comparable data are there for Israel and Tonga?
- 18 years are reported by both, from 2008 to 2025.
- How do Israel and Tonga rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc) immunizati?
- Israel ranks 46th and Tonga ranks 46th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.